

# Search for a genetic cause of variably protease-sensitive prionopathy

Yuan Lian<sup>1</sup>, Keisi Kotobelli<sup>2</sup>, Stacey Hall<sup>3</sup>, Michael E Talkowski<sup>4</sup>, Anne O'Donnell-Luria<sup>4,5</sup>,  
Sonia M Vallabh<sup>1,6,7,8</sup>, Brian S Appleby<sup>2†</sup>, Eric Vallabh Minikel<sup>1,6,7,8†</sup>

1. Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
2. National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH, 44106, USA
3. Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
4. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
5. Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA
6. McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
7. Department of Neurology, Harvard Medical School, Boston, MA, 02115, USA
8. Prion Alliance, Cambridge, MA, 02139, USA

†Correspondence to: [bsa35@case.edu](mailto:bsa35@case.edu) or [eminikel@broadinstitute.org](mailto:eminikel@broadinstitute.org)

## Abstract

Variably protease-sensitive prionopathy (VPSPr) is a rare, atypical subtype of prion disease in which many patients exhibit a family history of dementia. Rare protein-coding variants in *PRNP*, which are causal for all known forms of genetic prion disease, have been ruled out in all VPSPr cases to date, leading to suspicion that VPSPr could be caused by variants in other genes or by non-coding variation in or near *PRNP*. We performed exome sequencing and targeted sequencing of *PRNP* non-coding regions on genomic DNA from autopsy-confirmed VPSPr patients (N=67) in order to search for a possible genetic cause. Our search identified no potentially causal variants for VPSPr. The common polymorphism *PRNP* M129V was the largest genetic risk factor for VPSPr, with an odds ratio of 7.0. Other variants in and near *PRNP* exhibited association to VPSPr risk only in proportion to their linkage disequilibrium with M129V, and upstream expression quantitative trait loci showed no evidence of independent association to VPSPr risk. We cannot rule out the possibility of causal variants hiding in regions or classes of genetic variation that our search did not canvas. Nevertheless, our data support the classification of VPSPr as a sporadic prion disease.

## Author Summary

Prion disease is caused by misfolding of the prion protein (PrP), and can be either sporadic genetic, or acquired. Acquired cases arising from infection through dietary or medical routes are exceedingly rare today (<1% of cases). Sporadic cases occur apparently at random, without any major genetic risk factors, and are not passed down to subsequent generations. All cases of genetic prion disease to date have been traced to DNA changes that alter the amino acid sequence of PrP, and children of people with genetic prion disease are at 50/50 risk of inheriting these autosomal dominant DNA changes. Variably protease sensitive prionopathy, or VPSPr, is a rare and unusual subtype of prion disease, in which there are no changes in PrP's amino acid

sequence, and yet, a high proportion of patients appear to have a family history of dementia, although none to date have had family members diagnosed with prion disease specifically. VPSPr is currently categorized as a sporadic prion disease, but it has been speculated that it may have a genetic cause in a different gene or in a region of the PrP gene that does not change the amino acid sequence. Here we performed DNA sequencing on 67 VPSPr cases to search for a genetic cause. We found no DNA changes that could potentially cause VPSPr. While it is difficult to prove the negative — a causal genetic change could still exist in some part of the genome where we did not search — our data support the notion that VPSPr is truly sporadic in nature, and that risk of VPSPr is not transmitted in families.

## Introduction

Prion disease is an invariably fatal neurodegenerative disease caused by autocatalytic templating of the prion protein (PrP) into a misfolded conformer known as a prion<sup>1</sup>. Early on, the generation of PrP species resistant to limited protease digestion was considered an obligate pathological hallmark of prion disease<sup>2–4</sup>. Later, it was determined that only some proportion of misfolded pathologic PrP is protease-resistant, and that this proportion differs between prion strains<sup>5</sup>. Variably protease-sensitive prionopathy (VPSPr) is a subtype of human prion disease named for the paucity or total absence of protease-resistant PrP in the brain<sup>6,7</sup>. VPSPr possesses several additional features that distinguish it from other types of human prion disease<sup>8</sup>. Histopathologically, it features larger spongiform vacuoles than sporadic Creutzfeldt Jakob disease (sCJD), and a distinct pattern of PrP deposition. Transmission to humanized mice has been challenging<sup>9,10</sup>, although the transmissibility of VPSPr has been established in bank voles<sup>11</sup>. Cerebrospinal fluid (CSF) real-time quaking induced conversion (RT-QuIC) is less sensitive than in sCJD, being positive in 7 out of 10 cases in the literature<sup>12–15</sup>, and sometimes only with low peak amplitude. VPSPr progresses slower than sCJD, with a disease course averaging 2.5 years<sup>7</sup>, and is often misdiagnosed as a non-Alzheimer's disease dementia. Many VPSPr patients exhibit co-occurring tau, amyloid beta, or synuclein pathology<sup>8,16–20</sup>.

Most prion disease cases (85%) are sporadic, a term which in prion disease is defined to mean lacking any known environmental or molecular genetic cause. A minority (15%) are genetic, caused by *PRNP* protein-coding variants, some but not all of which are highly penetrant<sup>21</sup>. A smaller minority of cases (<1%) are acquired through infection, via exposure to misfolded prions in the diet or through medical procedures<sup>22</sup>. *PRNP* M129V (rs1799990), a common polymorphism, modifies both disease risk and phenotypic features across all three etiologies<sup>23</sup>. In sCJD, the 129M allele and particularly the 129MM genotype are overrepresented, whereas in VPSPr, the 129V allele is overrepresented. Protein-coding variants in *PRNP* have been ruled out in all reported VPSPr patients, leading to classification of VPSPr as a sporadic, rather than genetic, prion disease. Nevertheless, a large proportion of VPSPr patients have family history positive for dementia — 15/36 (42%) in the largest reported cohort<sup>8</sup>, including a majority (60%) of cases with the 129VV genotype. This has led to speculation that VPSPr might be a form of genetic prion disease with a cause other than *PRNP* coding variants<sup>7,8</sup>.

In this study, we set out to identify a genetic cause of VPSPr. We evaluated the potential genetic architecture of VPSPr by examining disease prevalence and the rate at which positive

family history is observed. We determined that if a causal genetic variant exists, it would be only modestly penetrant, yet extremely rare and conferring a high fold increase in lifetime risk of prion disease, with odds ratio (OR) >1,000. Such a variant could be discovered through sequencing tens of cases and comparing their allele frequencies to those of publicly available population control datasets. We obtained DNA from 67 autopsy-confirmed VPSPr cases and performed exome sequencing and deep sequencing of 152 kb centered on the *PRNP* locus, including non-coding regions, and compared these to the Genome Aggregation Database (gnomAD) and controls. No potentially causal variants were identified, suggesting that VPSPr may be genuinely sporadic in etiology.

## Results

### Hypothesized genetic architecture of VPSPr and rationale for study design

To define a search strategy for genomic variants that could hypothetically cause VPSPr, we first needed to consider how rare the causal genetic variants would need to be, and how strongly enriched in cases over controls they would need to be (Table 1). In the simplified case of 1 variant-positive relative, the family history rate could be explained by a single variant with 42% penetrance. The total prevalence of all forms of prion disease is estimated at 1 in 6,239 deaths, or 0.016% lifetime risk<sup>24</sup>. VPSPr in turn has comprised 88/3,931 prion disease cases (2.2%) ascertained by the U.S. National Prion Disease Pathology and Surveillance Center since the discovery of VPSPr<sup>25</sup>. The highest allele frequency (AF) of a causal variant would occur if 100% of VPSPr cases were caused by a single variant.


We included all of these assumptions (Table 1) into a previously described framework<sup>26</sup> for determining the highest allele frequency that a disease-causing variant could have in the general population, and obtained a maximum credible AF of  $4.3e-6$ . Note that allowing multiple causal variants, no single one of which explains all cases, would only further lower this frequency. Considering multiplex families, where a 42% family history rate could arise from, for example, 2 variant-positive relatives with penetrance 21%, would also lower this frequency. Moreover, our filtering strategy is inherently conservative because it only removes genetic variants when even the lower bound of the 95% confidence interval on their allele frequency is above the filtering threshold. Based on these considerations, we selected  $4.3e-6$ , or 1 in 232,558, as our AF filtering threshold. This seems plausible because VPSPr is several times rarer than genetic prion disease caused by highly penetrant *PRNP* coding variants, which collectively are estimated to have a genetic prevalence of ~1 in 50,000 people<sup>27,28</sup>.

We explored the relationship between positive family history and OR for known causal *PRNP* variants in genetic prion disease (Figure 1A). Updating our OR estimates using gnomAD v4.1 data<sup>29</sup> and comparing to the proportion of cases with family history using previously reported data<sup>21</sup>, we fit a log-linear model. VPSPr, with its 42% positive family history, would be most likely to arise from variants with OR > 1,000. The constraints of OR > 1,000 and AF <  $4.3e-6$  define a range of possible positions that a VPSPr-causing variant could occupy in the scatterplot of AF in the general population versus AF in VPSPr cases (Figure 1B). Given this hypothesized genetic architecture, we determined that sequencing VPSPr cases alone is a valid strategy to identify causal variants. A genome-wide association study (GWAS), which is designed to identify common variants (AF > 0.1%) of small effect (OR < 2) would not be appropriate. A case/control

exome study, which may identify slightly rarer variants (AF > 0.01%) with slightly larger effects (OR 2-10) is also not appropriate. Instead, the same strategy used for solving highly penetrant Mendelian diseases — sequencing only cases and filtering their genetic variants based on population AF information — is appropriate.

**Table 1. Parameters used to calculate the maximum credible allele frequency for VPSPr.**

Parameter	Estimate	Rationale
Penetrance	42%	Most conservative assumption, assuming just 1 variant-positive relative who has lived through the risk period
Prevalence of all prion disease	0.016%	1 in 6,239 deaths <sup>24</sup>
VPSPr as proportion of prion disease	2.2%	88/3,931 cases in U.S. since discovery of VPSPr in 2008 <sup>25</sup>
Proportion of cases attributable to most common variant	100%	Most conservative assumption because it yields the highest tolerated allele frequency
Maximum credible allele frequency	4.3e-6	Calculated from above parameters using the approach of Whiffin & Minikel et al <sup>26</sup>



**Figure 1. Hypothetical odds ratio of VPSPr-causing variants and implications for genomic search strategy. A)** Odds ratio (OR; Fisher exact test) for PRNP coding variants that cause genetic prion disease, based on previously reported case data<sup>21</sup> and gnomAD v4.1 allele frequencies, versus prevalence of family history among cases as reported<sup>21</sup>. **B)** Range of possible outcomes for VPSPr-causing variants, see text for reasoning.

### Characteristics of VPSPr cohort

We obtained DNA from N=67 autopsy-confirmed VPSPr cases from the U.S. National Prion Disease Pathology Surveillance Center (NPDPSC; Table 2). All 3 codon 129 genotypes were represented in our cohort, with 129VV comprising a majority (67%, 45/67) of cases, consistent with prior reports. Age at death differed between genotypes (P = 0.0012, Type I ANOVA, Table 2), shifting younger as the number of V alleles increased (Tukey post-hoc test: P = 0.0031 for VV vs. MM, P = 0.051 for VV vs. MV, P = 0.54 for MV vs. MM). Disease duration was also modified by codon 129 genotype, being longest for heterozygous MV individuals (P = 5.0e-6, Type I ANOVA, Table 2), similar to other forms of prion disease<sup>23</sup> (Tukey post-hoc test: P = 4.7e-6 for VV vs. MV, P = 0.11 for VV vs. MM, P = 0.18 for MV vs. MM). The sex distribution did not deviate significantly from 50/50 (P = 0.46, binomial test), and sex was not associated to age at death (P = 0.42, Type I ANOVA) nor disease duration (P = 0.57, Type I ANOVA) and showed no confounding with codon 129 genotype (P = 0.28, Fisher exact test). The reporting physician indicated the presence or absence of family history of neurological disease in 19 cases, of whom 10 (52%) had a positive family history, all of whom were 129VV.


<b>Codon 129 genotype</b>	<b>N</b>	<b>Age at death (years, mean±SD)</b>	<b>Disease duration (years, mean±SD)</b>	<b>Sex</b>	<b>Family history of neurological disease</b>
MM	9	79±8	2.7±0.7	7M/2F	0% (0/1)
MV	13	75±10	3.8±1.7	8M/5F	0% (0/2)
VV	45	69±8	1.6±1.0	22M/23F	62% (10/16)
<b>all</b>	<b>67</b>	<b>72±9</b>	<b>2.1±1.4</b>	<b>37M/30F</b>	<b>53% (10/19)</b>

**Table 2. Characteristics of VPSPr DNA cohort.**

### Exome sequencing

We performed exome sequencing to test the hypothesis that protein-coding variants in one or more genes other than PRNP may cause VPSPr (Figure 2). To account for batch effects, we filtered using the lower of two allele frequencies: the filtering allele frequency (FAF) in gnomAD v4.1, which is based on the continental population with the highest frequency<sup>26</sup>, or the allele

frequency among 18,371 internal controls, which are Mendelian disease cases and unaffected family members also sequenced by the Broad Institute Genomics Platform. Implementing our allele frequency filtering strategy in the genomic browsing software *seqr*<sup>30</sup> resulted in no hits with >1 allele among our 67 VPSPr cases. To exclude that this null result was due to an overly aggressive filtering strategy, we also plotted the allele count in VPSPr cases against the combined filtering allele frequency obtained from our two sources (Figure 2A). This confirmed that relaxing the allele frequency filter, even by 100-fold, would not have resulted in any hits. A handful of low-frequency (AF > 0.1%) frequency variants appeared more common in VPSPr cases than controls, but all were indels, suggesting some artifact, possibly due to the brain origin of our DNA, versus the blood origin of most comparators. This analysis argues that no single protein-coding variant could cause VPSPr.



**Figure 2. Exome sequencing results. A)** Analysis of single variants. Each point is one variant. Allele count (AC) in VPSPr cases (y axis) versus filtering allele frequency combined from *gnomAD* v4.1 and internal controls for SNPs (black) and indels (gray). **B)** Analysis collapsing by gene. Each point is one gene. Total allele count (AC) of variants below frequency threshold (see inset key).

We next considered the possibility that VPSPr is genetically homogeneous but highly allelically heterogeneous — with many different causal variants, all in the same gene. Although our lack of concurrently sequenced controls does not permit a gene burden test per se, it is common to group variants by gene after applying an allele frequency filter to see if any genes are enriched for rare variants in cases. In such an approach, long genes such as *TTN* tend to be among the top hits simply because they have more opportunities for rare variation to arise. To mitigate this, we plotted the count of protein-altering variants below the filtering threshold in our VPSPr cases versus the length of coding sequence in each gene (Figure 2B). No genes had an anomalously large number of variants relative to their size. Moreover, no genes reached an allele count (AC) of 16, which is the AC at which our hypothesized OR of 1,000 intersects the filtering allele frequency (Figure 1B). Relaxing the frequency filter by 5-fold did not change this. This argues that VPSPr is not caused by protein-altering variants in any single gene.


Finally, because tau, amyloid beta, and alpha synuclein co-pathology have been observed in VPSPr brains (see Introduction), we also considered the possibility that VPSPr could be

associated with familial forms of other neurodegenerative diseases. We used *seqr*<sup>30</sup> to search for ClinVar<sup>31</sup> pathogenic and likely pathogenic variants in a curated list of 25 Mendelian disease genes associated with neurodegeneration<sup>32</sup>. This search identified among our VPSPr cases 1 heterozygous carrier of the recessive *PRKN* R275W variant, which when homozygous causes juvenile-onset parkinsonism, as well as 1 heterozygous carrier of the *GBA* N409S variant, a common risk factor for Parkinson disease. No other hits were found, suggesting VPSPr is not associated with other familial dementias.

### Targeted sequencing of the *PRNP* locus

Prior to this study, *PRNP* coding variants had been ruled out in all of our VPSPr cases, but non coding variation has never previously been assessed. We used targeted capture to perform deep sequencing, obtaining ~1,000X depth across almost all of a 152 kb region surrounding *PRNP*, including the lead SNPs for upstream expression quantitative trait loci (eQTLs) identified by the Genotype-Tissue Expression project (GTEx v8)<sup>33</sup> (Figure 3A). We compared allele counts in VPSPr to 2 control data sources: 76,215 gnomAD v4 genomes, and 298 genetic prion disease cases and carriers (see Methods). The latter were previously sequenced using the exact same targeted capture protocol, and we reasoned that they are suitable as controls because in all cases their genetic cause has already been identified as a *PRNP* coding variant, eliminating any expectation of a further non-coding contributor.

No non-coding *PRNP* variants present in >1 VPSPr case passed the allele frequency filter. As with the exome analysis, plotting the VPSPr allele count versus control allele frequency revealed that even a dramatic relaxation of the frequency filter would not have altered this result (Figure 3B). As expected, *PRNP* M129V as well as several common variants in linkage disequilibrium with it appeared visibly enriched in VPSPr (Figure 3B).




**Figure 3. Targeted sequencing of PRNP.** **A)** Targeted sequencing depth grouped by 100 base pair increments, shown relative to position of genes and relevant SNPs in GRCh38 coordinates. **B)** Analysis of single variants. Each point is one variant. Allele count (AC) in VPSPr cases (y axis) versus filtering allele frequency combined from gnomAD v4.1 genomes 76,215 and internal controls (genetic prion disease cases with known PRNP coding variants). **C)** Allele frequency (AF) among VPSPr cases (y axis) versus genetic prion disease (gPrD; x axis). Variants linked to 129V are purple and those linked to 129M are green. Dashed lines indicate ORs of 0.01, 0.1, 10, and 100. **D)** The lesser odds ratio (OR) of VPSPr versus gnomAD v4 genomes or gPrD (y axis) versus linkage to 129V (x axis).

We sought to examine further whether M129V is the sole risk variant, or whether VPSPr cases are enriched for a 129V haplotype harboring other potential risk-conferring variants. When we plotted the allele frequency of variants in and around PRNP in VPSPr cases versus genetic prion disease cases, most variants aligned along the diagonal representing OR = 1 (Figure 3C). Nearly all 129V-linked variants were associated with risk, with  $1 < OR < 10$ , while nearly all 129M-linked variants were associated with protection, with  $0.1 < OR < 1$  (Figure 3C). To determine whether all risk associated with this haplotype could be attributed to 129V, we plotted each variant's linkage ( $r^2$ ) with 129V against its OR (Figure 3D). In this analysis, to be conservative, we used the lesser of the OR of VPSPr versus gnomAD v4 genomes or versus genetic prion disease cases. 129V had the single highest OR of any variant (OR = 7.0 relative to gnomAD non-Finnish Europeans; OR = 9.6 relative to gPrD cases), and most other variants were distributed along a diagonal where OR was proportional to  $r^2$  (Figure 3D). The 2 upstream eQTLs fell along this diagonal (Figure 3D), suggesting that they do not have any association with VPSPr independent of linkage to 129V.



The above observations would be consistent with all risk associated to the 129V haplotype being solely attributable to 129V itself. However, we also noticed a handful of variants with anomalously high or low OR, out of proportion to their linkage to 129V (Figure 3D). The populations of our cases and controls are not perfectly matched, and we considered all ORs without regards to any particular P value threshold, so such ORs could arise by chance. To further exclude that any of these might genuinely contribute risk, we also examined several properties of all the variants in and around *PRNP* more deeply.

Plotting OR versus position did not reveal any spatially coherent cluster of high- or low-OR variants distal from M129V (Figure 4A). In sporadic CJD, codon 129 heterozygosity confers dramatic protection (OR = 0.35 in a genotypic model), but risk for 129VV is lower than 129MM, thus, in an allelic model, the 129V allele is protective (OR = 0.78)<sup>34</sup>, opposite to VPSPr. Accordingly, all the same variants that conferred risk of VPSPr also conferred protection from sCJD according to GWAS summary statistics<sup>34</sup>, and vice versa, all explainable by linkage to codon 129 (Figure 4B). A handful of variants exhibited OR as high as 1.3 or as low as 0.8 in the sCJD GWAS without showing any signal in VPSPr, but the converse — variants associated with VPSPr but with sCJD — was not identified (Figure 4B), again suggesting no independent risk variants. A number of variants associated with lower risk of VPSPr are also associated with lower *PRNP* expression in tibial nerve, but the two signals were not linked by any clear positional pattern (Figure 4A and 4C). Plotting OR versus impact on tibial nerve expression aligned the variants along a diagonal, further suggesting that linkage with 129V likely underlies any appearance of an association between OR and tibial nerve expression (Figure 4D). The cerebellum eQTL is strongest further upstream of *PRNP*, in a region lacking strong OR signals (Figure 4A and 4E). 129V is not associated with cerebellar *PRNP* expression, and overall there was no correlation between cerebellum slope and OR (Figure 4F). All of the above observations are consistent with 129V being the sole *PRNP* causal risk allele for VPSPr.



**Figure 4. Further exploration of variants near PRNP.** All targeted sequencing variants here are filtered for PASS SNPs with allele frequency >0% and <100% in both VPSPr and gPrD. **A)** The lesser odds ratio (OR) of VPSPr compared to gnomAD v4 genomes or to gPrD (y axis), versus chromosomal position (GRCh38; x axis shared with B and C). **B)** Slope of tibial nerve PRNP cis-eQTL association (GTEx v8; y axis) versus chromosomal position (x axis). **C)** Slope of cerebellum PRNP cis-eQTL association (GTEx v8; y axis) versus chromosomal position (x axis). **D)** VPSPr OR as in (A) versus the reported OR from sCJD GWAS<sup>34</sup>. **E)** VPSPr OR as in (A) versus tibial nerve slope as in (B). **F)** VPSPr OR as in (A) versus cerebellum slope as in (C).

## Discussion

An elevated proportion of VPSPr cases possess a positive family history of apparently non-prion dementia, leading several investigators to speculate whether VPSPr has a genetic cause. Here, we examined the most obvious places where such a genetic cause might be found: protein coding sequences of non-*PRNP* genes, and non-coding sequence in and around *PRNP*, particularly variants linked to the known risk allele 129V. We did not identify any potentially causal variants. Our data are consistent with 129V as the sole genetic risk factor for VPSPr. Note that while its OR of 7.0 would be considered as a “strong” risk factor by the standards of common disease genetics, this is not strong for a rare disease. Given that prion disease has a baseline prevalence of 0.016%, variants would need to have OR > 1,000 to cause appreciable penetrance<sup>35</sup>.

Our study has limitations. We did not perform whole genome sequencing to look for non-coding variants in non-*PRNP* genes, and many classes of genetic variation would evade our search altogether, such as short tandem repeats (STRs) and structural variants (SVs)<sup>36</sup>. We chose not to sequence matched controls, so we are not able to apply the rigorous statistical controls to look for, and rule out, variants of small effect.

Our data may suggest that VPSPr is a truly sporadic prion disease, with no strong genetic risk factor. If true, this would mean that the relatives of VPSPr patients are not at any inherited disease risk. The prevalence of positive family history in VPSPr remains to be explained. Given the small sample size available, it could be a chance occurrence. Alternatively, it may relate to the longer disease duration and older age of onset for VPSPr, compared to sCJD. VPSPr presentations more similar to frontotemporal dementia (FTD) or Alzheimer disease may prompt clinicians to take more complete family histories, or may prompt family members to recall family history that is actually attributable to these more common dementias.

Overall, our study supports the classification of VPSPr as a sporadic prion disease.

## Methods

**Ethical approvals.** This study was approved by the Broad Institute’s Office of Research Subjects Protection (NHSR-5256).

**VPSPr samples.** All VPSPr patients were autopsy-confirmed at the U.S. National Prion Disease Pathology Surveillance Center (NPDPSC, Cleveland, OH). DNA was extracted from frozen brain tissue.

**Control datasets.** Internal controls for the exome analysis were 18,371 candidate Mendelian disease cases sequenced through the Broad Center for Mendelian Genomics (CMG). Internal controls for the targeted analysis were 257 deceased, autopsy-confirmed gPrD cases examined at NPDPSC plus 41 mostly asymptomatic participants in a gPrD mutation carrier cohort study at

Mass General Hospital<sup>37,38</sup>; all of these individuals harbored rare *PRNP* coding variants. Population control information was taken from gnomAD v4.1<sup>29</sup>, comprising a total of 807,192 exomes + genomes used for the VPSPr exome analysis, including 76,215 whole genomes relevant for non-coding portions of the *PRNP* targeted sequencing analysis. Linkage disequilibrium ( $r^2$ ) information was queried from gnomAD v2 using Hail<sup>39</sup>. eQTL information (GTEx v8)<sup>33</sup> was downloaded from [gtexportal.org](https://gtexportal.org).

**Filtering allele frequency calculations.** We used the approach previously described<sup>26</sup>. For each variant, the filtering allele frequency is the highest lower bound of the 95% confidence interval of the AF in any continental population. To convert our assumptions (Table 2) into a maximum credible allele frequency, we used the webapp available at <https://cardiodb.org/allelefrequencyapp/>

**Short read sequencing.** All sequencing was performed at the Genomics Platform at the Broad Institute. Exome sequencing used the standard germline exome v6 (SGEv6) product, with 40 ng of input DNA subjected to capture by custom baits (Twist Biosciences) against 37 Mb of protein coding exons and sequenced on NovaSeq 6000 S4 sequencers (Illumina). Targeted sequencing used a set of custom baits (Twist Biosciences) used previously<sup>37,38</sup>, targeting a 152 kb region surrounding *PRNP*, and sequenced on NovaSeq SP (Illumina). Variant calling was performed using DRAGEN 3.7.8. A resulting joint-called VCF file was imported directly into *seqr* for browser-based analysis, or parsed into a flat table format using a custom Python script to enable custom analyses in R.

**Exome analyses.** Genotypes from exomes were filtered for depth (DP)  $\geq 10$  and genotype quality (GQ)  $\geq 20$ . Sites were annotated using Variant Effect Predictor<sup>40</sup>. In cases of multiple functional annotations per variant, only the most severe consequence was retained. For grouped analyses, variants assigned to a non-missing gene symbol were filtered with MODERATE or HIGH impact, meaning missense or missense-like, and predicted protein truncating.

**Source code, and data availability.** All figures and statistics in this manuscript were generated using custom scripts in R 4.4.1. Genomic and phenotypic data for the Broad CMG cohort used for comparison is available via dbGaP accession numbers phs003047 and phs001272. Access is managed by a data access committee designated by dbGaP and is based on intended use of the requester and allowed use of the data submitter as defined by consent codes. Raw data and source code sufficient to reproduce the figures and statistics in this manuscript will be made available at <https://github.com/ericminikel/vpspr>

## Acknowledgments

This study was funded by the National Institutes of Health (R03 NS123786). Broad CMG control cohort sequencing was funded by NIH grants UM1 HG008900 and U01 HG011755, and *seqr* analysis platform by R01 HG009141. We thank Stephanie DiTroia for assistance with the *seqr* search strategy.

## **Competing interests**

EVM acknowledges speaking fees from Abbvie, Eli Lilly, and Vertex; consulting fees from Alnylam and Deerfield; research support from Eli Lilly, Gate Bio, Ionis, and Sangamo. SMV acknowledges speaking fees from Abbvie, Biogen, Eli Lilly, Illumina, and Ultragenyx; consulting fees from Alnylam and Invitae; research support from Eli Lilly, Gate Bio, Ionis, and Sangamo. BSA acknowledges research funding from CDC, NIH, CJD Foundation, and Ionis and consulting fees from Ionis, Sangamo, and Gate Bio, and royalties from Wolter Klower. AODL acknowledges consulting fees from Tome Biosciences, Ono Pharma USA, Addition Therapeutics, and Congenica; and research funding from Pacific Biosciences.

## **Author contributions**

Performed the experiments: YL, KK, SH. Supervised the research: MET, AODL, SMV, BSA, EVM. Analyzed the data: YL, EVM. Drafted the manuscript: EVM. Reviewed and approved the final manuscript: all authors.

## References

1. Prusiner SB. Prions. *Proc Natl Acad Sci U S A*. 1998 Nov 10;95(23):13363–13383. PMID: PMC33918
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. *Science*. 1982 Apr 9;216(4542):136–144. PMID: 6801762
3. Bendheim PE, Barry RA, DeArmond SJ, Stites DP, Prusiner SB. Antibodies to a scrapie prion protein. *Nature*. 1984 Aug 2;310(5976):418–421. PMID: 6431296
4. Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE. Purification and structural studies of a major scrapie prion protein. *Cell*. 1984 Aug;38(1):127–134. PMID: 6432339
5. Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. Eight prion strains have PrP(Sc) molecules with different conformations. *Nat Med*. 1998 Oct;4(10):1157–1165. PMID: 9771749
6. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alsheklee A, Castellani R, Cohen M, Barria MA, Gonzalez-Romero D, Belay ED, Schonberger LB, Marder K, Harris C, Burke JR, Montine T, Wisniewski T, Dickson DW, Soto C, Hulette CM, Mastrianni JA, Kong Q, Zou WQ. A novel human disease with abnormal prion protein sensitive to protease. *Ann Neurol*. 2008 Jun;63(6):697–708. PMID: PMC2767200
7. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I, Shimoji M, Langeveld JPM, Castellani R, Notari S, Crain B, Schmidt RE, Geschwind M, Dearmond SJ, Cairns NJ, Dickson D, Honig L, Torres JM, Mastrianni J, Capellari S, Giaccone G, Belay ED, Schonberger LB, Cohen M, Perry G, Kong Q, Parchi P, Tagliavini F, Gambetti P. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. *Ann Neurol*. 2010 Aug;68(2):162–172. PMID: PMC3032610
8. Notari S, Appleby BS, Gambetti P. Variably protease-sensitive prionopathy. *Handb Clin Neurol*. 2018;153:175–190. PMID: 29887135
9. Notari S, Xiao X, Espinosa JC, Cohen Y, Qing L, Aguilar-Calvo P, Kofskey D, Cali I, Cracco L, Kong Q, Torres JM, Zou W, Gambetti P. Transmission characteristics of variably protease-sensitive prionopathy. *Emerg Infect Dis*. 2014 Dec;20(12):2006–2014. PMID: PMC4257788
10. Diack AB, Ritchie DL, Peden AH, Brown D, Boyle A, Morabito L, Maclennan D, Burgoyne P, Jansen C, Knight RS, Piccardo P, Ironside JW, Manson JC. Variably protease-sensitive prionopathy, a unique prion variant with inefficient transmission properties. *Emerg Infect Dis*. 2014 Dec;20(12):1969–1979. PMID: PMC4257789
11. Nonno R, Notari S, Di Bari MA, Cali I, Pirisinu L, d'Agostino C, Cracco L, Kofskey D, Vanni I, Lavrich J, Parchi P, Agrimi U, Gambetti P. Variable Protease-Sensitive Prionopathy Transmission to Bank Voles. *Emerg Infect Dis*. 2019 Jan;25(1):73–81. PMID: PMC6302590
12. Franceschini A, Baiardi S, Hughson AG, McKenzie N, Moda F, Rossi M, Capellari S, Green A, Giaccone G, Caughey B, Parchi P. High diagnostic value of second generation CSF RT-

- QuIC across the wide spectrum of CJD prions. *Sci Rep.* 2017 Sep 6;7(1):10655. PMCID: PMC5587608
13. Rhoads DD, Wrona A, Foutz A, Blevins J, Glisic K, Person M, Maddox RA, Belay ED, Schonberger LB, Tatsuoka C, Cohen ML, Appleby BS. Diagnosis of prion diseases by RT QuIC results in improved surveillance. *Neurology.* 2020 Aug 25;95(8):e1017–e1026. PMID: 32571851
  14. Uchino A, Saito Y, Oonuma S, Murayama S, Yagishita S, Kitamoto T, Hasegawa K. An autopsy case of variably protease-sensitive prionopathy with Met/Met homogeneity at codon 129. *Neuropathol Off J Jpn Soc Neuropathol.* 2023 Dec;43(6):486–495. PMID: 37253452
  15. Zhang W, Orrú CD, Foutz A, Ding M, Yuan J, Shah SZA, Zhang J, Kotobelli K, Gerasimenko M, Gilliland T, Chen W, Tang M, Cohen M, Safar J, Xu B, Hong DJ, Cui L, Hughson AG, Schonberger LB, Tatsuoka C, Chen SG, Greenlee JJ, Wang Z, Appleby BS, Caughey B, Zou WQ. Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseases. *Acta Neuropathol (Berl).* 2024 Jan 17;147(1):17. PMID: 38231266
  16. Giaccone G, Di Fede G, Mangieri M, Limido L, Capobianco R, Suardi S, Grisoli M, Binelli S, Fociani P, Bugiani O, Tagliavini F. A novel phenotype of sporadic Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry.* 2007 Dec;78(12):1379–1382. PMCID: PMC2095610
  17. Rodríguez-Martínez AB, Garrido JM, Zarranz JJ, Arteagoitia JM, de Pancorbo MM, Atarés B, Bilbao MJ, Ferrer I, Juste RA. A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine/valine at codon 129: Case report. *BMC Neurol.* 2010 Oct 25;10:99. PMCID: PMC2987858
  18. Head MW, Lowrie S, Chohan G, Knight R, Scoones DJ, Ironside JW. Variably protease sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau,  $\alpha$  synuclein and A $\beta$  pathology. *Acta Neuropathol (Berl).* 2010 Dec;120(6):821–823. PMID: 21046409
  19. Cannon A, Bieniek KF, Lin WL, Notari S, Zou WQ, Gambetti P, Pedraza O, Graff-Radford NR, Ferman TJ, Dickson DW. Concurrent variably protease-sensitive prionopathy and amyotrophic lateral sclerosis. *Acta Neuropathol (Berl).* 2014 Aug;128(2):313–315. PMCID: PMC4161018
  20. Assar H, Topakian R, Weis S, Rahimi J, Trenkler J, Höftberger R, Aboulenein-Djamshidian F, Ströbel T, Budka H, Yull H, Head MW, Ironside JW, Kovacs GG. A case of variably protease-sensitive prionopathy treated with doxycyclin. *J Neurol Neurosurg Psychiatry.* 2015 Jul;86(7):816–818. PMID: 25575846
  21. Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, McLean CY, Tung JY, Yu LPC, Gambetti P, Blevins J, Zhang S, Cohen Y, Chen W, Yamada M, Hamaguchi T, Sanjo N, Mizusawa H, Nakamura Y, Kitamoto T, Collins SJ, Boyd A, Will

- RG, Knight R, Ponto C, Zerr I, Kraus TFJ, Eigenbrod S, Giese A, Calero M, de Pedro Cuesta J, Haik S, Laplanche JL, Bouaziz-Amar E, Brandel JP, Capellari S, Parchi P, Poleggi A, Ladogana A, O'Donnell-Luria AH, Karczewski KJ, Marshall JL, Boehnke M, Laakso M, Mohike KL, Kähler A, Chambert K, McCarroll S, Sullivan PF, Hultman CM, Purcell SM, Sklar P, van der Lee SJ, Rozemuller A, Jansen C, Hofman A, Kraaij R, van Rooij JGJ, Ikram MA, Uitterlinden AG, van Duijn CM, Exome Aggregation Consortium (ExAC), Daly MJ, MacArthur DG. Quantifying prion disease penetrance using large population control cohorts. *Sci Transl Med*. 2016 Jan 20;8(322):322ra9. PMID: PMC4774245
22. Will RG, Ironside JW. Sporadic and Infectious Human Prion Diseases. *Cold Spring Harb Perspect Med*. 2017 Jan 3;7(1). PMID: 27793965
23. Mead S, Lloyd S, Collinge J. Genetic Factors in Mammalian Prion Diseases. *Annu Rev Genet*. 2019 Dec 3;53:117–147. PMID: 31537104
24. Maddox RA, Person MK, Blevins JE, Abrams JY, Appleby BS, Schonberger LB, Belay ED. Prion disease incidence in the United States, 2003-2015. *Neurology*. 2019 Nov 22; PMID: 31757870
25. NPDPSC Table of Cases Examined | Pathology | School of Medicine | Case Western Reserve University [Internet]. 2024 [cited 2024 Oct 29]. Available from: <https://case.edu/medicine/pathology/research/national-prion-disease-pathology-surveillance-center/surveillance/tables-cases-examined>
26. Whiffin N, Minikel E, Walsh R, O'Donnell-Luria AH, Karczewski K, Ing AY, Barton PJR, Funke B, Cook SA, MacArthur D, Ware JS. Using high-resolution variant frequencies to empower clinical genome interpretation. *Genet Med Off J Am Coll Med Genet*. 2017;19(10):1151–1158. PMID: PMC5563454
27. Corbie R, Campbell T, Darwent L, Rudge P, Collinge J, Mead S. Estimation of the number of inherited prion disease mutation carriers in the UK. *Eur J Hum Genet EJHG*. 2022 Jun 27; PMID: 35754056
28. Minikel EV. How many patients do we have? [Internet]. CureFFI.org. 2022 [cited 2024 Oct 29]. Available from: <https://www.cureffi.org/2022/07/27/how-many-patients-do-we-have/>
29. Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, Alföldi J, Watts NA, Vittal C, Gauthier LD, Poterba T, Wilson MW, Tarasova Y, Phu W, Grant R, Yohannes MT, Koenig Z, Farjoun Y, Banks E, Donnelly S, Gabriel S, Gupta N, Ferreira S, Tolonen C, Novod S, Bergelson L, Roazen D, Ruano-Rubio V, Covarrubias M, Llanwarne C, Petrillo N, Wade G, Jeandet T, Munshi R, Tibbetts K, Genome Aggregation Database Consortium, O'Donnell-Luria A, Solomonson M, Seed C, Martin AR, Talkowski ME, Rehm HL, Daly MJ, Tiao G, Neale BM, MacArthur DG, Karczewski KJ. A genomic mutational constraint map using variation in 76,156 human genomes. *Nature*. 2024 Jan;625(7993):92–100. PMID: 38057664
30. Pais LS, Snow H, Weisburd B, Zhang S, Baxter SM, DiTroia S, O'Heir E, England E, Chao KR, Lemire G, Osei-Owusu I, VanNoy GE, Wilson M, Nguyen K, Arachchi H, Phu W, Solomonson M, Mano S, O'Leary M, Lovgren A, Babb L, Austin-Tse CA, Rehm HL, MacArthur DG, O'Donnell-Luria A. seqr: A web-based analysis and collaboration tool for rare disease



genomics. *Hum Mutat.* 2022 Jun;43(6):698–707. PMID: PMC9903206

31. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, Karapetyan K, Katz K, Liu C, Maddipatla Z, Malheiro A, McDaniel K, Ovetsky M, Riley G, Zhou G, Holmes JB, Kattman BL, Maglott DR. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* 2018 Jan 4;46(D1):D1062–D1067. PMID: PMC5753237
32. Mortberg MA, Vallabh SM, Minikel EV. Disease stages and therapeutic hypotheses in two decades of neurodegenerative disease clinical trials. *Sci Rep.* 2022 Oct 21;12(1):17708. PMID: PMC9587287
33. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science.* 2020 Sep 11;369(6509):1318–1330. PMID: PMC7737656
34. Jones E, Hummerich H, Viré E, Uphill J, Dimitriadis A, Speedy H, Campbell T, Norsworthy P, Quinn L, Whitfield J, Linehan J, Jaunmuktane Z, Brandner S, Jat P, Nihat A, How Mok T, Ahmed P, Collins S, Stehmann C, Sarros S, Kovacs GG, Geschwind MD, Golubjatnikov A, Frontzek K, Budka H, Aguzzi A, Karamujić-Čomić H, van der Lee SJ, Ibrahim-Verbaas CA, van Duijn CM, Sikorska B, Golanska E, Liberski PP, Calero M, Calero O, Sanchez Juan P, Salas A, Martínón-Torres F, Bouaziz-Amar E, Haïk S, Laplanche JL, Brandel JP, Amouyel P, Lambert JC, Parchi P, Bartoletti-Stella A, Capellari S, Poggi A, Ladogana A, Pocchiari M, Aneli S, Matullo G, Knight R, Zafar S, Zerr I, Booth S, Coulthart MB, Jansen GH, Glisic K, Blevins J, Gambetti P, Safar J, Appleby B, Collinge J, Mead S. Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome wide association study. *Lancet Neurol.* 2020 Oct;19(10):840–848. PMID: 32949544
35. Minikel EV, MacArthur DG. Publicly Available Data Provide Evidence against NR1H3 R415Q Causing Multiple Sclerosis. *Neuron.* 2016 Oct 19;92(2):336–338. PMID: PMC5123684
36. Collins RL, Brand H, Karczewski KJ, Zhao X, Alföldi J, Francioli LC, Khera AV, Lowther C, Gauthier LD, Wang H, Watts NA, Solomonson M, O'Donnell-Luria A, Baumann A, Munshi R, Walker M, Whelan CW, Huang Y, Brookings T, Sharpe T, Stone MR, Valkanas E, Fu J, Tiao G, Laricchia KM, Ruano-Rubio V, Stevens C, Gupta N, Cusick C, Margolin L, Genome Aggregation Database Production Team, Genome Aggregation Database Consortium, Taylor KD, Lin HJ, Rich SS, Post WS, Chen YDI, Rotter JI, Nusbaum C, Philippakis A, Lander E, Gabriel S, Neale BM, Kathiresan S, Daly MJ, Banks E, MacArthur DG, Talkowski ME. A structural variation reference for medical and population genetics. *Nature.* 2020;581(7809):444–451. PMID: PMC7334194
37. Vallabh SM, Minikel EV, Williams VJ, Carlyle BC, McManus AJ, Wennick CD, Bolling A, Trombetta BA, Urlick D, Nobuhara CK, Gerber J, Duddy H, Lachmann I, Stehmann C, Collins SJ, Blennow K, Zetterberg H, Arnold SE. Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease. *BMC Med.* 2020 Jun 18;18(1):140. PMID: PMC7302371
38. Vallabh SM, Mortberg MA, Allen SW, Kupferschmid AC, Kivisakk P, Hammerschlag BL, Bolling A, Trombetta BA, Devitte-McKee K, Ford AM, Sather LE, Duffy G, Rivera A, Gerber J, McManus AJ, Minikel EV, Arnold SE. Fluid Biomarkers in Individuals at Risk for Genetic

Prion Disease up to Disease Conversion. *Neurology*. 2024 Jul 23;103(2):e209506. PMID: PMC11226308

39. Hail Team. Hail 0.2 [Internet]. Available from: <https://github.com/hail-is/hail>

40. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, Flicek P, Cunningham F. The Ensembl Variant Effect Predictor. *Genome Biol*. 2016 Jun 6;17(1):122. PMID: PMC4893825